<?xml version="1.0" encoding="UTF-8"?>
<p id="Par3">The antigenic similarity between ZIKV and dengue virus (DENV), sharing approximately 54% of their amino acid envelope proteins, results in immunological cross-reactivity
 <sup>
  <xref ref-type="bibr" rid="CR21">21</xref>
 </sup>. 
 <italic>In vitro</italic> studies have shown that anti-DENV antibodies can both enhance and neutralize ZIKV infection
 <sup>
  <xref ref-type="bibr" rid="CR22">22</xref>–
  <xref ref-type="bibr" rid="CR26">26</xref>
 </sup>. In animal models, mice that received plasma with a low level of anti-DENV antibodies had a higher mortality rate after ZIKV infection than mice that received plasma without antibodies. However, all mice that received plasma with a high level of anti-DENV antibodies survived after ZIKV challenge and presented milder symptoms
 <sup>
  <xref ref-type="bibr" rid="CR22">22</xref>
 </sup>. Human plasma collected ≤100 days after PCR-confirmed DENV infection binds and cross-neutralizes ZIKV 
 <italic>in vitro</italic>. On the other hand, late-convalescent-phase plasma does not harbour durable, high levels of cross-neutralizing antibodies against ZIKV
 <sup>
  <xref ref-type="bibr" rid="CR27">27</xref>
 </sup>. However, the understanding of cross-neutralizing antibody responses among individuals with prior DENV exposure, particularly how these responses evolve over time and in various transmission contexts in flavivirus-endemic countries is quite unknown
 <sup>
  <xref ref-type="bibr" rid="CR28">28</xref>
 </sup>.
</p>
